Skip to main content

cystic fibrosis

Singing “Dare to Dream”

Posted on by

It was an honor to speak at the North American Cystic Fibrosis Conference in Nashville on November 1, 2019. It has been 30 years now since I was a part of the team that discovered the CFTR gene, which, when altered, causes cystic fibrosis (CF). Our challenging hunt for CFTR was energized by the promise that a genetic understanding of this terrible disease would one day lead to life-extending molecularly targeted treatments. I later wrote a song for everyone touched by this disease called, “Dare to Dream,” to capture the historic opportunity before us. Today, I concluded my remarks by singing this slightly updated version of the song to celebrate with everyone in the audience that life-sustaining molecularly targeted treatments are now available for 90 percent of people with CF. What a wonderful moment it was, and I’d like to share it with everyone who would like to Dare to Dream until the story of CF is history! Credit: CF Foundation


Dare to Dream: The Long Road to Targeted Therapies for Cystic Fibrosis

Posted on by

Jenny's 1989 diary entry next to a recent photo

When your world has been touched by a life-threatening disease, it’s hard to spend a lot of time dreaming about the future. But that’s exactly what Jenny, an 8-year-old girl with cystic fibrosis (CF), did 30 years ago upon hearing the news that I and my colleagues in Ann Arbor and Toronto had discovered the gene for CF [1,2]. Her upbeat diary entry, which you can read above, is among the many ways in which people with CF have encouraged researchers on the long and difficult road toward achieving our shared dream of effective, molecularly targeted therapies for one of the nation’s most common potentially fatal recessive genetic diseases, affecting more than 30,000 individuals in the United States [3].

Today, I’m overjoyed to say that this dream finally appears to have come true for about 90 percent of people with CF. In papers in the New England Journal of Medicine and The Lancet [4,5], two international teams, including researchers partly supported by NIH, report impressive results from phase 3 clinical trials of a triple drug therapy for individuals with CF and at least one copy of Phe508del, the most common CF-causing mutation. And Jenny happens to be among those who now stand to benefit from this major advance.

Now happily married and living in Colorado, Jenny is leading an active life, writing a children’s book and trying to keep up with her daughter Pippa Lou, whom you see with her in the photo above. In a recent email to me, her optimistic outlook continues to shine through: “I have ALWAYS known in my heart that CF will be cured during my lifetime and I have made it my goal to be strong and ready for that day when it comes. None of the advancements in care would be what they are without you.”

But there are a great many more people who need to be recognized and thanked. Such advances were made possible by decades of work involving a vast number of other researchers, many funded by NIH, as well as by more than two decades of visionary and collaborative efforts between the Cystic Fibrosis Foundation and Aurora Biosciences (now, Vertex Pharmaceuticals) that built upon that fundamental knowledge of the responsible gene and its protein product. Not only did this innovative approach serve to accelerate the development of therapies for CF, it established a model that may inform efforts to develop therapies for other rare genetic diseases.

To understand how the new triple therapy works, one first needs to understand some things about the protein affected by CF, the cystic fibrosis transmembrane regulator (CFTR). In healthy people, CFTR serves as a gated channel for chloride ions in the cell membrane, regulating the balance of salt and water in the lungs, pancreas, sweat glands, and other organ systems.

People with the most common CF-causing Phe508del mutation produce a CFTR protein with two serious problems: misfolding that often results in the protein becoming trapped in the cell’s factory production line called the endoplasmic reticulum; and deficient activation of any protein that does manage to reach its proper location in the cell membrane. Consequently, an effective therapy for such people needs to include drugs that can correct the CFTR misfolding, along with those than can activate, or potentiate, the function of CFTR when it reaches the cell membrane.

The new triple combination therapy, which was developed by Vertex Pharmaceuticals and recently approved by the Food and Drug Administration (FDA) [6], is elexacaftor-tezacaftor-ivacaftor (two correctors and one potentiator). This approach builds upon the success of ivacaftor monotherapy, approved by the FDA in 2012 for rare CF-causing mutations; and tezacaftor-ivacaftor dual therapy, approved by the FDA in 2018 for people with two copies of the Phe508del mutation.

Specifically, the final results from two Phase 3 multi-center, randomized clinical trials demonstrated the safety and efficacy of the triple combination therapy for people with either one or two copies of the Phe508del mutation—which represents about 90 percent of people with CF. Patients in both trials experienced striking improvements in a key measure of lung capacity (forced expiratory volume in 1 second) and in sweat chloride levels, which show if the drugs are working throughout the body. In addition, the triple therapy was generally safe and well tolerated, with less than 1 percent of patients discontinuing the treatment due to adverse effects.

This is wonderful news! But let’s be clear—we are not yet at our journey’s end when it comes to realizing the full dream of defeating CF. More work remains to be done to help the approximately 10 percent of CF patients whose mutations result in the production of virtually no CFTR protein, which means there is nothing for current drugs to correct or activate.

Beyond that, wouldn’t it be great if biomedical science could figure out a way to permanently cure CF, perhaps using nonheritable gene editing, so no one needs to take drugs at all? It’s a bold dream, but look how far a little dreaming, plus a lot of hard work, has taken us so far in Jenny’s life.   

In closing, I’d like to leave you with the chorus of a song, called “Dare to Dream,” that I wrote shortly after we identified the CF gene. I hope the words inspire not only folks affected by CF, but everyone who is looking to NIH-supported research for healing and hope.

Dare to dream, dare to dream,

All our brothers and sisters breathing free.

Unafraid, our hearts unswayed,

‘Til the story of CF is history.

References:

[1]. Identification of the cystic fibrosis gene: chromosome walking and jumping. Rommens JM, Iannuzzi MC, Kerem B, et al. Science 1989; 245:1059-1065.

[2]. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Riordan JR, Rommens JM, Kerem B, et al. Science 1989; 245:1066-73. Erratum in: Science 1989; 245:1437.

[3] Realizing the Dream of Molecularly Targeted Therapies for Cystic Fibrosis. Collins, FS. N Engl J Med. 2019 Oct 31. [Epub ahead of print]

[4]. Elexacaftor-Tezacaftor-Ivacaftor for CF with a Single Phe508del Mutation. Middleton P, Mall M, Drevinek P, et al.N Engl J Med. 2019 Oct 31. [Epub ahead of print]

[5] Efficacy and safety of the elexacaftor/tezacaftor/ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Heijerman H, McKone E, Downey D, et al. Lancet. 2019 Oct 31. [Epub ahead of print]

[6] FDA approves new breakthrough therapy for cystic fibrosis. FDA News Release, Oct. 21, 2019.

Links:

Cystic Fibrosis (Genetics Home Reference/National Library of Medicine/NIH)

Research Milestones (Cystic Fibrosis Foundation, Bethesda, MD)

Wheezie Stevens in “Bubbles Can’t Hold Rain,” by Jennifer K. McGlincy

NIH Support: National, Heart, Lung and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Center for Advancing Translational Sciences


Thirtieth Anniversary of Cystic Fibrosis Gene Discovery

Posted on by

In 1989, the gene that causes cystic fibrosis (CF), was discovered by a collaborative research effort involving my own lab at the University of Michigan, Ann Arbor, and colleagues at the Hospital for Sick Children, Toronto. This year marks the 30th anniversary of the discovery, which has yielded life-sustaining targeted therapies for many kids born with this rare disease. The Cystic Fibrosis Foundation asked me recently to talk about “the long, tough road” traveled to find the gene hunt and the ongoing research commitment to help people with CF. Courtesy of Cystic Fibrosis Foundation.

2018 Warren Alpert Foundation Prize Symposium

Posted on by

I was deeply honored to be among the five recipients of the 2018 Warren Alpert Foundation Prize. All five recipients were recognized for their discoveries in contributing to the development of life-altering treatments for cystic fibrosis (CF). The other recipients were: Paul Negulescu, Vertex Pharmaceuticals, Boston; Bonnie Ramsey, University of Washington School of Medicine and Seattle Children’s Research Institute; Lap-Chee Tsui, The Academy of Sciences of Hong Kong; Michael Welsh, University of Iowa, Iowa City. We were recognized at an afternoon symposium titled Cystic Fibrosis: From Gene Discovery to Basic Biology to Precision Medicines. The symposium was held at Harvard Medical School, Boston, on October 4, 2018. The video posted here shows my presentation that afternoon. But if you would like to see more, there is a full video of this fantastic symposium.


Another Milestone in the Cystic Fibrosis Journey

Posted on by

Avalyn Mahoney

Caption: Two-year-old Avalyn is among the cystic fibrosis patients who may be helped by targeted drugs.
Credit: Brittany Mahoney

As NIH Director, I often hear stories of how people with serious diseases—from arthritis to Zika infection—are benefitting from the transformational power of NIH’s investments in basic science. Today, I’d like to share one such advance that I find particularly exciting: news that a combination of three molecularly targeted drugs may finally make it possible to treat the vast majority of patients with cystic fibrosis (CF), our nation’s most common genetic disease.

First, a bit of history! The first genetic mutation that causes CF was discovered by a collaborative effort between my own research lab at the University of Michigan, Ann Arbor, and colleagues at the Hospital for Sick Children in Toronto—more than 25 years ago [1]. Years of hard work, supported by the National Institutes of Health and the Cystic Fibrosis Foundation, painstakingly worked out the normal function of the protein that is altered in CF, called the cystic fibrosis transmembrane regulator (CFTR). Very recently new technologies, such as cryo-EM, have given researchers the ability to map the exact structure of the protein involved in CF.

Among the tens of thousands of CF patients who stand to benefit from the next generation of targeted drugs is little Avalyn Mahoney of Cardiff by the Sea, CA. Just a few decades ago, a kid like Avalyn—who just turned 2 last month—probably wouldn’t have made it beyond her teens. But today the outlook is far brighter for her and so many others, thanks to recent advances that build upon NIH-supported basic research.


Next Page